Study guide

3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes

Key Takeaways Explain This Topic AI

In clinical enzymology, analytical assays are calibrated under zero-order kinetics where substrate is present in vast excess ( [ S ] ≫ K m [S] \gg K_m [ S ] ≫ K m ​ ), ensuring that reaction velocity ( V V V ) is independent of substrate concentration and directly proportional to functional enzyme activity.

Cardiac Troponins (cTnI and cTnT) are the gold standards for diagnosing acute myocardial infarction due to exceptional cardiac specificity and prolonged diagnostic elevation (up to 7-14 days), whereas CK-MB normalizes within 48-72 hours, which is why classic teaching uses it to detect early recurrent infarction.

Hepatocellular injury is differentiated from obstructive cholestatic pathology by contrasting aminotransferases (ALT, AST) with canalicular markers (ALP, GGT); an AST:ALT De Ritis ratio > 2.0 >2.0 > 2.0 strongly indicates alcoholic liver disease.

Lipase is more pancreas-specific than amylase and stays elevated longer after acute pancreatitis, while a low amylase-to-creatinine clearance ratio suggests macroamylasemia.

An elevated ALP with a normal GGT points to bone or placental ALP rather than a hepatobiliary source.

Last updated: October 2026

Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes

Clinical enzymology measures the catalytic activity (or mass) of enzymes released from injured tissue. The board expects you to know the kinetics that make enzyme assays work, the time course of cardiac biomarkers, and the patterns that separate hepatocellular injury, cholestasis, bone disease, and pancreatitis. Endocrinology and toxicology, which share the Clinical Chemistry endocrine-and-toxicology blueprint area, are covered in the next two sections, and bilirubin and ammonia are covered in the liver function section.

1. Principles of Clinical Enzymology

Enzymes are biological catalysts that accelerate chemical reactions without being consumed, functioning by lowering the free activation energy ( Δ G ‡ \Delta G^\ddagger Δ G ‡ ) required to convert substrate ( S S S ) into product ( P P P ): E + S ⇌ k − 1 k 1 [ E S ] → k 2 E + P E + S \xrightleftharpoons[k_{-1}]{k_1} [ES] \xrightarrow{k_2} E + P E + S k 1 ​ k − 1 ​ ​ [ ES ] k 2 ​ ​ E + P

Michaelis-Menten Kinetics: First-Order vs. Zero-Order

The mathematical relationship between substrate concentration [ S ] [S] [ S ] and reaction velocity ( V V V ) is described by the Michaelis-Menten equation : V = V max ⁡ [ S ] K m + [ S ] V = \frac{V_{\max} [S]}{K_m + [S]} V = K m ​ + [ S ] V m a x ​ [ S ] ​ Where:

V max ⁡ V_{\max} V m a x ​ is the maximum achievable reaction velocity when all enzyme catalytic sites are saturated with substrate.

K m K_m K m ​ (Michaelis constant) is the substrate concentration at which the reaction velocity is half-maximal ( 1 2 V max ⁡ \frac{1}{2} V_{\max} 2 1 ​ V m a x ​ ), reflecting enzyme-substrate affinity. Reaction Velocity (V)

  • |
  • Vmax --+ - - - - - - - - - - - - - - - - - - - - - - - - - - - - ZERO-ORDER KINETICS
  • | .............. ([S] >> Km; Rate depends
  • | . ' solely on [Enzyme])
  • 1/2Vmax| - - - - - - - - - - - . '
  • | . '
  • | . '
  • | . ' FIRST-ORDER KINETICS
  • | . ' ([S] << Km; Rate depends on [Substrate])
  • | . '
  • +-------------------+---------------------------------> Substrate Concentration [S]
  • 0 Km

First-Order Kinetics ( [ S ] ≪ K m [S] \ll K_m [ S ] ≪ K m ​ ): At low substrate concentrations, [ S ] [S] [ S ] in the denominator is negligible compared to K m K_m K m ​ , simplifying the equation to V ≈ ( V max ⁡ / K m ) [ S ] V \approx (V_{\max} / K_m) [S] V ≈ ( V m a x ​ / K m ​ ) [ S ] . Here, the reaction rate is directly proportional to substrate concentration. First-order kinetics are used in assays designed to measure substrate concentration (e.g., measuring serum glucose via hexokinase or measuring urea via urease).

Zero-Order Kinetics ( [ S ] ≫ K m [S] \gg K_m [ S ] ≫ K m ​ ): In diagnostic enzymology, the analytical goal is to measure enzyme activity , not substrate. Assays are engineered with substrate present in vast excess (typically [ S ] ≥ 10 − 100 × K m [S] \ge 10-100 \times K_m [ S ] ≥ 10 − 100 × K m ​ ). Under these saturated conditions, K m + [ S ] ≈ [ S ] K_m + [S] \approx [S] K m ​ + [ S ] ≈ [ S ] , simplifying the equation to V = V max ⁡ V = V_{\max} V = V m a x ​ . Because all catalytic active sites are constantly saturated, the reaction velocity is independent of substrate concentration and is directly proportional to the active enzyme concentration in patient serum.

Units of Enzyme Activity

Because circulating enzymes exist in minute mass quantities with variable specific activities, clinical laboratories quantify catalytic activity rather than absolute mass concentration:

International Unit (IU): The quantity of enzyme that catalyzes the conversion of 1.0 μ mol 1.0\text{ }\mu\text{mol} 1.0 μ mol of substrate to product per minute under specified, standardized conditions of temperature ( 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ), pH, and substrate excess ( 1 IU = 1 μ mol/min 1\text{ IU} = 1\text{ }\mu\text{mol/min} 1 IU = 1 μ mol/min ). Concentrations are reported as IU/L or U/L.

Katal (kat): The SI unit of catalytic activity, defined as the quantity of enzyme catalyzing the conversion of 1.0 mole 1.0\text{ mole} 1.0 mole of substrate per second ( 1.0 kat = 1.0 mol/s 1.0\text{ kat} = 1.0\text{ mol/s} 1.0 kat = 1.0 mol/s ). Conversion: 1 IU = 16.67 nkat 1\text{ IU} = 16.67\text{ nkat} 1 IU = 16.67 nkat .

Isoenzymes and Isoforms

Isoenzymes are physically distinct forms of an enzyme that catalyze the same biochemical reaction but differ in primary amino acid structure, electrophoretic mobility, immunological reactivity, and tissue distribution. Isoenzymes arise from distinct genetic loci or alternative splicing, whereas isoforms represent post-translational modifications of a specific isoenzyme.

2. Cardiac Biomarkers in Acute Coronary Syndrome and Heart Failure +---------------------------------------------------------------------------------------+

  • | ACUTE MYOCARDIAL INFARCTION BIOMARKER TIMELINE |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | BIOMARKER | INITIAL RISE | PEAK ELEVATION | DURATION TO NORMALIZATION |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | Myoglobin | 1 - 3 hours | 6 - 8 hours | 24 hours |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | Cardiac Troponin I| 3 - 6 hours | 12 - 24 hours | 7 - 10 days |
  • | (cTnI) | | | |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | Cardiac Troponin T| 3 - 6 hours | 12 - 24 hours | 10 - 14 days |
  • | (cTnT) | | | |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | CK-MB | 4 - 6 hours | 18 - 24 hours | 48 - 72 hours |
  • | (Mass / Activity) | | | (Ideal for reinfarction) |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | Total CK | 4 - 8 hours | 24 - 36 hours | 3 - 4 days |
  • +-------------------+---------------+-------------------+-------------------------------+
  • | LD-1 > LD-2 Flip | 10 - 24 hours | 48 - 72 hours | 10 - 14 days |
  • | (Historical) | | | (Obsolete) |
  • +-------------------+---------------+-------------------+-------------------------------+
  • Cardiac Troponins (cTnI and cTnT)

The troponin complex regulates calcium-mediated actin-myosin contraction in striated muscle, comprising three subunits:

Troponin C (TnC): Calcium-binding subunit (identical in skeletal and cardiac muscle; not used clinically).

Troponin I (TnI): Inhibitory subunit; possesses a unique 31-amino-acid N-terminal sequence expressed exclusively in myocardium ( cardiac Troponin I, cTnI ).

Troponin T (TnT): Tropomyosin-binding subunit; expressed in myocardium with minor cross-reactivity in diseased skeletal muscle ( cardiac Troponin T, cTnT ).

Clinical Profile: Cardiac troponins are the undisputed gold standard for evaluating acute coronary syndromes (ACS). Following myocardial necrosis, troponins begin rising in peripheral blood within 3 to 6 hours , reach a peak at 12 to 24 hours , and remain diagnostically elevated for 7 to 10 days (cTnI) and up to 10 to 14 days (cTnT) . High-sensitivity troponin assays (hs-cTn) detect minute elevations within 1 to 3 hours, allowing rapid rule-in and rule-out algorithms.

Creatine Kinase (CK) and CK-MB Isoenzyme

Creatine kinase (CK) is a dimeric enzyme ( 82 kDa 82\text{ kDa} 82 kDa ) catalyzing the reversible phosphorylation of creatine by ATP. It exists as three cytoplasmic isoenzymes composed of two polypeptide subunits: M (muscle) and B (brain) :

CK-BB (CK-1): Brain, prostate, gastrointestinal tract, and bladder. Migrates fastest toward the anode on electrophoresis. Rarely elevated in serum except in extensive bowel infarction, CNS damage, or small cell carcinoma.

CK-MB (CK-2): Cardiac muscle (comprises 15-20% of total cardiac CK; skeletal muscle contains <2-3%). Migrates with intermediate mobility.

CK-MM (CK-3): Skeletal muscle (comprises 97-99% of skeletal muscle CK) and myocardium (comprises 80% of cardiac CK). Migrates slowest (closest to cathode).

Diagnostic Utility of CK-MB: CK-MB rises within 4 to 6 hours post-AMI, peaks at 18 to 24 hours , and returns to baseline within 48 to 72 hours . Because troponins remain elevated for up to two weeks, they cannot identify recurrent ischemic injury occurring a few days after an index infarction. Classic board teaching names CK-MB as the marker for detecting reinfarction (early recurrent myocardial infarction) occurring 3 to 7 days after an initial event, because an abrupt re-elevation of CK-MB stands out against its normalized baseline. Current universal-definition criteria also accept a fresh rise of more than 20% in serial high-sensitivity troponin values as evidence of reinfarction.

CK-MB Relative Index (CKI): Differentiates cardiac injury from massive skeletal muscle trauma: CK-MB Relative Index (%) = CK-MB Mass [ng/mL] Total CK Activity [U/L] × 100 \text{CK-MB Relative Index (\%)} = \frac{\text{CK-MB Mass [ng/mL]}}{\text{Total CK Activity [U/L]}} \times 100 CK-MB Relative Index (%) = Total CK Activity [U/L] CK-MB Mass [ng/mL] ​ × 100

Index < 2.5-3.0%: Skeletal muscle damage.

Index > 3.0-5.0%: Definitive myocardial injury.

Myoglobin

Myoglobin is a small cytoplasmic heme protein ( 17.8 kDa 17.8\text{ kDa} 17.8 kDa ) found in skeletal and cardiac muscle. Due to its low molecular weight, it is released rapidly upon myocyte membrane injury, rising within 1 to 3 hours , peaking at 6 to 8 hours , and clearing via renal excretion within 24 hours . While it lacks cardiac specificity (elevated in skeletal muscle trauma, intramuscular injections, and renal failure), myoglobin possesses an exceptional negative predictive value : a normal myoglobin level at 3 to 4 hours post-chest pain virtually rules out acute myocardial infarction.

Natriuretic Peptides in Congestive Heart Failure (CHF)

B-Type Natriuretic Peptide (BNP) and NT-proBNP: Synthesized by ventricular cardiomyocytes as pre-proBNP in response to increased ventricular wall tension, diastolic stretch, and volume overload. Cleaved into inactive NT-proBNP (76 amino acids, half-life ≈ 70 minutes \approx 70\text{ minutes} ≈ 70 minutes , cleared renally) and active BNP (32 amino acids, half-life ≈ 20 minutes \approx 20\text{ minutes} ≈ 20 minutes , cleared via neutral endopeptidases and natriuretic peptide receptors).

Diagnostic Cutoffs for Heart Failure:

BNP: < 100 pg/mL <100\text{ pg/mL} < 100 pg/mL rules out CHF (high negative predictive value); > 400 pg/mL >400\text{ pg/mL} > 400 pg/mL strongly indicates acute heart failure.

NT-proBNP: < 300 pg/mL <300\text{ pg/mL} < 300 pg/mL rules out CHF; age-stratified rule-in cutoffs: > 450 pg/mL >450\text{ pg/mL} > 450 pg/mL (age < 50 <50 < 50 ), > 900 pg/mL >900\text{ pg/mL} > 900 pg/mL (age 50 − 75 50-75 50 − 75 ), and > 1800 pg/mL >1800\text{ pg/mL} > 1800 pg/mL (age > 75 >75 > 75 ).

  • 3. Hepatobiliary and Pancreatic Enzymes
  • Aminotransferases: AST and ALT

Aspartate Aminotransferase (AST / SGOT): Catalyzes the transfer of an amino group between L-aspartate and α \alpha α -ketoglutarate to form oxaloacetate and glutamate. Found in both cytoplasm (30%) and mitochondria (70%) of hepatocytes, cardiac myocytes, skeletal muscle, kidneys, and erythrocytes.

Alanine Aminotransferase (ALT / SGPT): Catalyzes the transfer of an amino group between L-alanine and α \alpha α -ketoglutarate to form pyruvate and glutamate. ALT is purely cytoplasmic and localized primarily in hepatocytes, making it far more liver-specific than AST .

The De Ritis Ratio (AST/ALT)

Normal De Ritis Ratio: ≈ 0.8 − 1.0 \approx 0.8 - 1.0 ≈ 0.8 − 1.0 .

Ratio < 1.0 (ALT > AST): Characteristic of acute viral hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), acute biliary obstruction, and toxic exposure. In viral hepatitis, both enzymes reach > 10 − 50 × >10-50 \times > 10 − 50 × the upper limit of normal (ULN), with ALT exceeding AST.

Ratio > 2.0 (AST > ALT by at least 2:1): Highly suggestive of alcoholic liver disease / alcoholic hepatitis . Mechanisms:

Alcohol induces preferential injury to hepatocyte mitochondria, releasing mitochondrial AST.

Pyridoxal-5'-phosphate (vitamin B 6 B_6 B 6 ​ , an essential cofactor for both enzymes) is depleted in chronic alcoholism; this deficiency inhibits ALT apoenzyme synthesis far more severely than AST synthesis.

Ratio > 1.0 in Non-Alcoholic Disease: When an established chronic liver disorder (e.g., chronic hepatitis C) transitions from mild hepatitis to advanced hepatic cirrhosis , the De Ritis ratio flips from < 1.0 <1.0 < 1.0 to > 1.0 >1.0 > 1.0 due to impaired sinusoidal clearance of AST by hepatic endothelial cells.

Alkaline Phosphatase (ALP) and Gamma-Glutamyltransferase (GGT)

Alkaline Phosphatase (ALP): Zinc and magnesium metalloenzyme that hydrolyzes monophosphate esters at an alkaline optimal pH ( 9.0 − 10.5 9.0-10.5 9.0 − 10.5 ). Localized in the microvillar membranes of bile canaliculi, bone osteoblasts, intestinal mucosa, and the placenta.

Clinical Indications: Marked elevations ( > 3 − 10 × >3-10 \times > 3 − 10 × ULN) occur in cholestasis/biliary obstruction (cholelithiasis, pancreatic head adenocarcinoma) and osteoblastic bone diseases (Paget disease of bone, osteosarcoma, healing fractures, rickets/osteomalacia, osteoblastic bone metastases from prostate cancer). Physiological elevations occur during normal third-trimester pregnancy (placental ALP) and adolescent growth spurts (bone ALP).

Differentiating ALP Isoenzymes by Heat Stability: Serum is incubated at 56 ∘ C 56^\circ\text{C} 5 6 ∘ C for 10 minutes before testing (remember: "Bone burns, Liver lives" ):

Placental ALP (Regan/Nagao isoenzyme): Extremely heat-stable; resists denaturation even at 65 ∘ C 65^\circ\text{C} 6 5 ∘ C .

Intestinal ALP: Intermediate stability (50-60% inactivated).

Liver ALP: Moderately stable (50-70% activity remains at 56 ∘ C 56^\circ\text{C} 5 6 ∘ C ).

Bone ALP: Most heat-labile ; > 80 − 90 % >80-90\% > 80 − 90% denatured/destroyed at 56 ∘ C 56^\circ\text{C} 5 6 ∘ C (<20% residual activity).

Differentiating Bone vs. Liver ALP Using GGT:

Gamma-Glutamyltransferase (GGT): Membrane-bound enzyme transferring glutamyl groups from peptides to amino acids. GGT is abundant in biliary canalicular epithelial cells, kidney, and pancreas, but is completely absent from bone and placenta .

Diagnostic Matrix:

↑ ALP + ↑ GGT ⟶ \uparrow \text{ALP} + \uparrow \text{GGT} \longrightarrow ↑ ALP + ↑ GGT ⟶ Hepatobiliary source (cholestasis, biliary obstruction).

↑ ALP + Normal GGT ⟶ \uparrow \text{ALP} + \text{Normal GGT} \longrightarrow ↑ ALP + Normal GGT ⟶ Bone etiology (Paget disease, osteosarcoma, rickets) or physiological pregnancy.

GGT as Alcohol Biomarker: GGT is induced by hepatic microsomal enzyme stimulation; it is a sensitive screening marker for chronic alcohol consumption and tracks therapeutic compliance during alcohol cessation.

Pancreatic Enzymes: Amylase and Lipase

Amylase (AMS): Hydrolase that cleaves α \alpha α -1,4-glucosidic bonds in starch and glycogen. Consists of two isoenzyme families: P-type (pancreatic) and S-type (salivary) . In acute pancreatitis, serum amylase rises within 2 to 12 hours , peaks at 24 hours , and normalizes rapidly within 3 to 5 days .

Macroamylasemia: Benign condition where amylase complexes with circulating immunoglobulins (IgA or IgG) to form a high-molecular-weight macromolecule ( > 200 kDa >200\text{ kDa} > 200 kDa ) that cannot pass through the renal glomerular filtration barrier. Characterized by persistently elevated serum amylase accompanied by abnormally low urine amylase and a low amylase-to-creatinine clearance ratio ( ACCR < 1 % \text{ACCR} < 1\% ACCR < 1% , normal 2 − 5 % 2-5\% 2 − 5% ): ACCR (%) = Urine Amylase × Serum Creatinine Serum Amylase × Urine Creatinine × 100 \text{ACCR (\%)} = \frac{\text{Urine Amylase} \times \text{Serum Creatinine}}{\text{Serum Amylase} \times \text{Urine Creatinine}} \times 100 ACCR (%) = Serum Amylase × Urine Creatinine Urine Amylase × Serum Creatinine ​ × 100

Lipase (LPS): Hydrolyzes glycerol esters of long-chain fatty acids in the presence of colipase and bile salts. Lipase is superior to amylase for diagnosing acute pancreatitis because it is virtually specific to pancreatic acinar tissue (salivary glands produce no lipase), rises within 4 to 8 hours , peaks at 24 hours , and remains elevated for 8 to 14 days , providing an extended diagnostic window in patients presenting days after pain onset.

4. Diagnostic Enzyme Profile Summary

Enzyme Abbreviation Major Tissue Sources Major Diagnostic Indications Analytical / Clinical Pearls

Alanine Aminotransferase ALT (SGPT) Liver parenchymal cells Acute viral hepatitis, toxic hepatitis, liver necrosis Highly liver-specific; cytoplasmic; ALT > AST in acute hepatitis

Aspartate Aminotransferase AST (SGOT) Liver, heart, skeletal muscle, kidney, RBCs Hepatocellular injury, alcoholic hepatitis, muscle trauma Mitochondrial and cytoplasmic; AST:ALT > 2:1 in alcoholic liver injury

Alkaline Phosphatase ALP Biliary canaliculi, bone osteoblasts, placenta Cholestasis, biliary obstruction, Paget disease, rickets Inactivated by heat: "Bone burns, Liver lives"; elevated in pregnancy and childhood

Gamma-Glutamyltransferase GGT Canalicular epithelium, renal tubules, pancreas Biliary obstruction, chronic alcohol abuse Absent in bone; differentiates hepatobiliary from skeletal ALP elevations

Creatine Kinase CK Skeletal muscle, myocardium, brain Myocardial infarction, rhabdomyolysis, muscular dystrophy CK-MB is ideal for detecting reinfarction within 3-7 days

Lactate Dehydrogenase LD / LDH Ubiquitous (heart, RBCs, liver, muscle, kidneys) Hemolytic anemia, tissue infarction, germ cell tumors Hemolysis causes massive false elevation; historical LD1 > LD2 flip in AMI

Lipase LPS Pancreatic acinar cells Acute pancreatitis Highly specific for pancreas; remains elevated for 8-14 days

Amylase AMS Pancreas (P-type), salivary glands (S-type) Acute pancreatitis, mumps, macroamylasemia Clears rapidly (3-5 days); low ACCR (<1%) indicates macroamylasemia

Cholinesterase PChE (Pseudocholinesterase) Liver, plasma Organophosphate insecticide poisoning, succinylcholine sensitivity Inhibited by organophosphates; low levels cause prolonged surgical apnea